Intellia Therapeutics (NASDAQ:NTLA) Given Buy Rating at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. Several other equities research analysts have also weighed in on NTLA. Guggenheim dropped their price target on Intellia Therapeutics from $55.00 […]
HC Wainwright reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. Several other equities research analysts have also weighed in on NTLA. Guggenheim dropped their price target on Intellia Therapeutics from $55.00 […]
